Why Anti-Aging Clinics Are Adding Peptide Therapy to Their Menu

Peptide therapy has moved from the margins of longevity practice into a standard menu item, and the reasons are as much commercial as clinical. Both are worth examining before adding it, because the categories differ enormously in how well-supported they are — and a practice that treats them as one thing will eventually promise something it cannot deliver.

Why Practices Are Adding It

Patients are asking. Search interest and direct patient requests have grown substantially. A practice that cannot have an informed conversation loses the patient to one that can — frequently to a source with no clinical oversight at all.

It fits the existing model. Longevity and aesthetic practices already operate cash-pay, already do baseline testing, already run follow-up cadences. Peptide therapy slots into infrastructure that exists.

Recurring rather than episodic. Unlike a procedure, therapy generates refills and monitoring visits.

It complements rather than competes. Peptides sit alongside hormone optimisation, aesthetics and nutraceuticals rather than cannibalizing them.

The Honest Evidence Picture

This is where practices get into trouble. "Peptides" is not one category, and the evidence ranges from large controlled trials to almost nothing.

A practice that presents all six with equal confidence is setting up disappointment in at least four of them.

Setting Expectations That Survive Month Three

The most common failure in this category is a timeline mismatch. Patients told to expect visible change in weeks abandon protocols that operate on a six-month scale.

Realistic framing: sleep depth often shifts within two weeks on GH secretagogues; energy and recovery over roughly six weeks; measurable body composition change at eight to twelve weeks; skin changes at twelve weeks or more, because collagen remodelling is slow and no formulation shortens it.

Our realistic results timeline covers this in patient-facing terms and is useful to hand out.

Measure something objective. Body composition by a consistent method, IGF-1 for secretagogues, standardized photography for skin protocols. Without a baseline, neither you nor the patient can distinguish a working protocol from an expensive one.

The Risks to Plan For

Regulatory volatility. Compounding status for several peptides has moved through 2026. A protocol that becomes unavailable mid-course is a clinical and reputational problem. Track it, or partner with someone who does.

Sourcing. The research-chemical market is large and easy to find. Patients who cannot access a compound through you may source it themselves, unsupervised. That is a conversation worth having explicitly rather than leaving to chance.

Angiogenic compounds and oncological history. BPC-157 and GHK-Cu both have angiogenic activity. Patients with malignancy or recent oncological surgery warrant specific discussion.

Athletes. Most of this category is prohibited in tested sport, BPC-157 by name. Any patient competing under an anti-doping code needs to know before starting.

Overpromising longevity. No peptide has been demonstrated to extend human lifespan. Practices that imply otherwise are making a claim the evidence does not support.

Starting Sensibly

Start with the categories where evidence is strongest and monitoring is clearest — hormone optimisation and GH secretagogues with IGF-1 tracking, topical GHK-Cu for dermal endpoints. Build the evaluation and follow-up workflow. Expand into the more speculative categories, if at all, with framing that matches the evidence.

Our clinical protocol reference covers monitoring by category, and getting started as a prescriber covers onboarding.

Frequently Asked Questions

Why are anti-aging clinics adding peptide therapy?

Patient demand, a fit with existing cash-pay and follow-up infrastructure, recurring rather than episodic revenue, and complementarity with hormone optimisation and aesthetics.

Which peptide categories have the best evidence?

GLP-1 receptor agonists have large controlled human trials. GH secretagogues have reasonable human data on body composition. Topical GHK-Cu has controlled studies on skin appearance. Tissue-repair peptides and longevity peptides such as Epitalon have substantial preclinical but minimal human evidence.

How long before patients see results?

Sleep changes often within two weeks on GH secretagogues, energy and recovery around six weeks, measurable body composition change at eight to twelve weeks, and skin changes at twelve weeks or more.

What are the main risks of offering peptide therapy?

Regulatory volatility mid-protocol, patients self-sourcing from unregulated suppliers, angiogenic compounds in patients with oncological history, anti-doping exposure for competing athletes, and overpromising longevity outcomes the evidence does not support.

Do peptides extend lifespan?

No peptide has been demonstrated to extend human lifespan. The evidence is preclinical or mechanistic. What can be discussed are intermediate outcomes such as sleep, body composition and skin appearance.

What should a practice start with?

Categories where evidence is strongest and monitoring clearest — hormone optimisation and GH secretagogues with IGF-1 tracking, and topical GHK-Cu for dermal endpoints — while the evaluation and follow-up workflow is established.